跳至主要内容
临床试验/NCT03917589
NCT03917589已完成不适用

Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS

Rennes University Hospital5 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2019年6月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
350
试验地点
5
主要终点
Difference of the proportion of patients with >= 1 relapse between the two groups

研究概览

简要总结

Multiple Sclerosis (MS) is most prevalent among women of childbearing age. The post-partum (PP) period is a critical phase in MS patients, during which a recrudescence of disease activity is expected. Different strategies have been assessed in the prevention of post-partum relapse. High dose methylprednisolone was evaluated in a case control study with historical controls but the positive results have not been confirmed.

In this study, the main objective will be to compare the risk of relapse in the 6 months PP period between patients treated systematically by high dose methylprednisolone after delivery compared to patients who didn't receive a systematic treatment.

The second objective will be focused on the comparison of the disease activity and disability progression in patients who have resumed early a Disease Modifying Drug (DMD) after delivery vs patients who haven't.

详细描述

Even if two small case control studies underlined the positive effect of high dose methylprednisolone on the relapse risk in the PP period in MS, these data have to be confirmed by a larger study. The impact of such a strategy remains also uncertain concerning the risk of long term disability. In this project, the investigators will also analyze the influence of the delay of DMD reintroduction after delivery on the relapse risk but also on the risk of disability. The results will have an important role in the therapeutic management of the post-partum period in MS patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
15 Years 至 49 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • Relapsing MS patients according to MacDonald criteria 2010
  • Age between 15 and 49 years old at the pregnancy
  • Age between 18 and 51 years old when filling the questionnaire of the study
  • At least one full pregnancy with live birth after the beginning of the MS diagnosis
  • At least one neurological visit during the 12 months period after the delivery
  • At least one neurological visit per year in the 12 months preceding the pregnancy
  • Pregnancy must occur between 01/2007 and 01/2017 In case of several pregnancies per woman, only the first one occurring in the period will be analyzed
  • Having received information on the protocol and not having expressed opposition to participating in the study.

排除标准

  • Patients who have received Immunoglobulines or plasma exchanges after the delivery in prevention of a relapse
  • Patients presenting a SPMS or PPMS form at the beginning of pregnancy
  • Protected persons referred to in Articles L. 1121-6 to L. 1121-9 of the code of public health (eg minors, persons deprived of liberty, ..) except nursing mothers postpartum.

结局指标

主要结局

Difference of the proportion of patients with >= 1 relapse between the two groups

时间窗: 6 months

proportion of patients with \>= 1 relapse during the six-month period after delivery between the patients who have systematically been treated by high-dose corticosteroids after the delivery; and patients who haven't been systematically treated by high-dose corticosteroids.

次要结局

  • Difference of the proportion of patients with >= 1 relapse(6 months)
  • Difference of the annualized relapse rate(two years)
  • Difference of the time to first relapse(Date of delivery)
  • Difference of the disability progression(2 years)
  • Difference of percentage of with Gadolinium enhancing lesions(6 months)
  • Difference of the number of Gadolinium enhancing lesions(6 months)

研究者

发起方
Rennes University Hospital
申办方类型
Other
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验